NeOnc Technologies to Present Phase 1 NEO212-01 Dose-Escalation Results for CNS Cancer Treatment
Key Insights
NeOnc Technologies will host an investor conference call on March 4, 2026, to present initial Phase 1 dose-escalation data from the NEO212-01 clinical trial evaluating their bioconjugated temozolomide platform for CNS malignancies (search).
The presentation will include safety and toxicity data, dose-escalation observations, pharmacokinetic findings, and planned regulatory next steps from the Phase 1/2 clinical trial.
The company's NEO212 therapeutic is part of a proprietary drug development platform designed to overcome blood-brain barrier (search) challenges and is currently advancing under FDA Fast-Track status.
NeOnc Technologies Holdings (search), Inc. (Nasdaq: NTHI) announced it will host an investor conference call on March 4, 2026, to present initial data from the Phase 1 dose-escalation portion of the NEO212-01 Phase 1/2 clinical trial. The multi-Phase 2 clinical-stage biopharmaceutical company is evaluating its proprietary bioconjugated temozolomide (TMZ) platform in an oral formulation for patients with central nervous system (CNS) malignancies.
Clinical Trial Update and Data Presentation
The conference call, scheduled for 6:00 a.m. Pacific Time / 9:00 a.m. Eastern Time, will feature members of NeOnc's management team alongside independent members of the company's Scientific Advisory Board (SAB). The discussion will include comprehensive updates on the Phase 1 dose-escalation portion of the NEO212-01 clinical trial, covering safety and toxicity data, dose-escalation observations, pharmacokinetic findings, and planned regulatory next steps.
Dr. Henry S. Friedman, Deputy Director of the Preston Robert Tisch Brain Tumor (search) Center at Duke University (search) and independent member of NTHI's Scientific Advisory Board, will participate in the presentation. Dr. Alexandra Miller, Chief of Neuro-oncology for the Brain Tumor Program at NYU Langone Health and also an independent SAB member, will join the discussion.
NEO Drug Development Platform
NeOnc Technologies focuses on developing central nervous system therapeutics designed to address persistent challenges in overcoming the blood-brain barrier (search). The company's NEO drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038.
The proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas (search). NeOnc's NEO100 and NEO212 therapeutics are currently in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status.
Intellectual Property and Partnerships
The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions.
The management team presenting the data will include Amir Heshmatpour, Chief Executive Officer, Executive Chairman and President; Dr. Thomas C. Chen, Chief Medical Officer and Chief Scientific Officer; Dr. Josh Neman, Chief Clinical Officer; and Keithly Garnett, Chief Financial Officer.